Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $786000.0.

  • Tg Therapeutics' Amortizatization of Intangibles fell 5674.19% to $786000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 1566.94%. This contributed to the annual value of $7.0 million for FY2024, which is 21234.35% up from last year.
  • Tg Therapeutics' Amortizatization of Intangibles amounted to $786000.0 in Q3 2025, which was down 5674.19% from $1.3 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Amortizatization of Intangibles high stood at $2.5 million for Q4 2022, and its period low was -$409000.0 during Q2 2021.
  • Its 5-year average for Amortizatization of Intangibles is $907157.9, with a median of $763000.0 in 2023.
  • As far as peak fluctuations go, Tg Therapeutics' Amortizatization of Intangibles surged by 427169.81% in 2021, and later tumbled by 6999.61% in 2023.
  • Quarter analysis of 5 years shows Tg Therapeutics' Amortizatization of Intangibles stood at $2.3 million in 2021, then grew by 9.75% to $2.5 million in 2022, then tumbled by 70.0% to $763000.0 in 2023, then soared by 122.41% to $1.7 million in 2024, then crashed by 53.68% to $786000.0 in 2025.
  • Its Amortizatization of Intangibles was $786000.0 in Q3 2025, compared to $1.3 million in Q2 2025 and $1.3 million in Q1 2025.